Publications by authors named "De Phung"

Claim this Profile
R
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
Vassilios Aslanis, Khalid Abd-Elaziz, Robert J Slack, Anne Brinch, Lise Gravelle, De Phung

Cancer Chemother Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment.
Vassilios Aslanis, Michael Gray, Robert J Slack, Fredrik R Zetterberg, Dimitar Tonev, De Phung

Clin Drug Investig· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE).
Erin E Gaughan, Tom M Quinn, Andrew Mills, Annya M Bruce, Jean Antonelli, De Phung

Am J Respir Crit Care Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate-Severe Atopic Dermatitis.
Diamant Thaçi, Dave Singh, Mark Lee, Helen Timmis, Dominique Jacobs, De Phung

J Clin Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Andrew J Armstrong, Ping Lin, Celestia S Higano, Peter Iversen, Cora N Sternberg, De Phung

Eur Urol Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, De Phung

N Engl J Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
Dana E Rathkopf, Tomasz M Beer, Yohann Loriot, Celestia S Higano, Andrew J Armstrong, De Phung

JAMA Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
Mary-Ellen Taplin, Andrew J Armstrong, Ping Lin, Andrew Krivoshik, De Phung

J Urol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
Tomasz M Beer, Kurt Miller, Bertrand Tombal, David Cella, De Phung

Eur J Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Joshi J Alumkal, Simon Chowdhury, Yohann Loriot, Cora N Sternberg, Johann S de Bono, De Phung

Clin Genitourin Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Andrew J Armstrong, Fred Saad, De Phung, Carl Dmuchowski, Neal D Shore

Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.
Nancy Devlin, Michael Herdman, Marco Pavesi, De Phung, Shevani Naidoo

Health Qual Life Outcomes· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer.
Konstantina Skaltsa, Cristina Ivanescu, Shevani Naidoo, De Phung, Stefan Holmstrom

Target Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to M.A.N. Şendur et al and J. Michels.
David F Penson, Andrew J Armstrong, Raoul Concepcion, Neeraj Agarwal, Carl Olsson, De Phung

J Clin Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
David F Penson, Andrew J Armstrong, Raoul Concepcion, Neeraj Agarwal, Carl Olsson, De Phung

J Clin Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Neal D Shore, Simon Chowdhury, Arnauld Villers, Laurence Klotz, D Robert Siemens, De Phung

Lancet Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, De Phung

Eur Urol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of enzalutamide for metastatic castration-resistant prostate cancer.
Suman Bhattacharya, Mohammad Hirmand, De Phung, Steve van Os

Ann N Y Acad Sci· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Yohann Loriot, Kurt Miller, Cora N Sternberg, Karim Fizazi, Johann S De Bono, De Phung

Lancet Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, De Phung

N Engl J Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, De Phung

Lancet Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
Konstantina Skaltsa, Louise Longworth, Cristina Ivanescu, De Phung, Stefan Holmstrom

Value Health· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.
William R Schelman, Glenn Liu, George Wilding, Thomas Morris, De Phung

Invest New Drugs· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
Nicholas D James, Armelle Caty, Heather Payne, Michael Borre, Bernard A Zonnenberg, De Phung

BJU Int· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
Nicholas D James, Armelle Caty, Michael Borre, Bernard A Zonnenberg, Philippe Beuzeboc, De Phung

Eur Urol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis